Compare Dicks Sporting Goods Inc (DKS) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Enveric Biosciences Inc — how do they compare? Dicks Sporting Goods Inc trades at $136.39 (market cap $13.26B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Dicks Sporting Goods Inc is far larger — about 1950× Enveric Biosciences Inc's market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Enveric Biosciences Inc for 14 Days on average.
| DKS | ENVB | |
|---|---|---|
Market Cap | $13.26B | $6.80M |
Volume | 2,292,035 | 64,867 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $10.80 |
52-Week Low | $121.15 | $1.27 |
Typical Hold Time | 19 Days | 14 Days |
Enterprise Value | $20.31B | -$1.49M |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $135.99, up 3.67% today, with a bearish technical signal but strong fundamentals including a P/E of 14.86 and ROE of 18.47%. Recent earnings show mixed results, with a Q2 2026 miss, while revenue grew to $13.44B in 2025. The stock faces headwinds from a securities class action lawsuit, but analysts maintain a buy consensus with a $153.30 price target.
The outlook is cautious due to legal risks and a bearish technical trend, but solid profitability and valuation metrics offer support. Upside potential exists if legal issues resolve and earnings rebound, though investor sentiment is tempered by near-term uncertainties. Risks include litigation outcomes and competitive pressures in retail.
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
